Adverse events: malignancy · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether oral alkylating agents ± steroids changes adverse events ‐ malignancy at final compared with placebo/no treatment/steroids (very low certainty).
1 finding from 1 review
Primary: investigator‐rated good/excellent control of symptoms · people with moderate to severe chronic hand eczema
Oral retinoids: alitretinoin 30 mg leads to higher primary: investigator‐rated good/excellent control of symptoms compared with placebo (high certainty).
1 finding from 1 review
Primary: participant‐rated good/excellent control of symptoms · people with moderate to severe chronic hand eczema
Oral retinoids: alitretinoin 30 mg leads to higher primary: participant‐rated good/excellent control of symptoms… compared with placebo (high certainty).
1 finding from 1 review
Adverse effects: headache · people with moderate to severe chronic hand eczema
Oral retinoids: alitretinoin 30 mg leads to higher primary: adverse events ‐ headache Folluw‐up: 48 weeks to 72 weeks compared with placebo (high certainty).
1 finding from 1 review
Secondary: investigator‐rated reduction in severity in TLSSc and mTLSSd · people with moderate to severe chronic hand eczema
The review found no eligible studies for this question.
1 finding from 1 review
Primary: investigator‐rated good/excellent control of symptoms · people with moderate to severe chronic hand eczema
Oral retinoids: alitretinoin 10 mg leads to higher primary: investigator‐rated good/excellent control of symptoms compared with placebo (high certainty).
1 finding from 1 review
Primary: participant‐rated good/excellent control of symptoms · people with moderate to severe chronic hand eczema
Oral retinoids: alitretinoin 10 mg leads to higher primary: participant‐rated good/excellent control of symptoms compared with placebo (high certainty).
1 finding from 1 review
Primary outcome 3: Adverse events · people with moderate to severe chronic hand eczema
Oral retinoids: alitretinoin 10 mg showed no clear difference in primary: all adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Secondary: investigator‐rated reduction in severity of TLSSd · people with moderate to severe chronic hand eczema
1 finding from 1 review
Recurrent seizure at 6 months · children with febrile seizures
Intermittent oral or rectal diazepam probably leads to lower recurrent seizure at 6 months compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Recurrent seizure at 12 months · children with febrile seizures
Intermittent oral or rectal diazepam probably leads to lower recurrent seizure at 12 months compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Recurrent seizure at 18 months · children with febrile seizures
Intermittent oral or rectal diazepam may leads to lower recurrent seizure at 18 months compared with placebo or no treatment (low certainty).
1 finding from 1 review
Recurrent seizure at 24 months · children with febrile seizures
Intermittent oral or rectal diazepam leads to lower recurrent seizure at 24 months compared with placebo or no treatment (high certainty).
1 finding from 1 review
Recurrent seizure at 36 months · children with febrile seizures
Intermittent oral or rectal diazepam may leads to lower recurrent seizure at 36 months compared with placebo or no treatment (low certainty).
1 finding from 1 review
Recurrent seizure at 48 months · children with febrile seizures
Intermittent oral or rectal diazepam probably leads to lower recurrent seizure at 48 months compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Recurrent seizure at 60 months or greater · children with febrile seizures
It is very uncertain whether intermittent oral or rectal diazepam changes recurrent seizure at 60 months or greater compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Complete cure, at least 3 months after the end of treatment · People with American cutaneous and mucocutaneous leishmaniasis
Oral miltefosine (50 mg for 28 days) probably leads to higher complete cure, at least 3 months after the end of treatment compared with placebo (same regimen) (moderate certainty).
1 finding from 1 review
Adverse effects (number of participants who had the event) · People with American cutaneous and mucocutaneous leishmaniasis
Oral miltefosine (50 mg for 28 days) probably leads to higher adverse effects (number of participants who had the event) compared with placebo (same regimen) (moderate certainty).
1 finding from 1 review
Recurrence · People with American cutaneous and mucocutaneous leishmaniasis
Oral miltefosine (50 mg for 28 days) showed no clear difference in recurrence compared with placebo (same regimen) (low certainty).
1 finding from 1 review
FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis
The review found no eligible studies for this question.
2 findings from 1 review